Previous 10 | Next 10 |
Iovance is a leader in TIL cell therapy for solid tumor patients. Iovance is readying its BLA for lifileucel in treatment of melanoma. Iovance has adequate financial footing for its near term needs but little margin for error. This is my first take on Iovance ( IOVA ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
SAN CARLOS, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appoint...
A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing applicati...
One of the patterns we like to see with insider buying is a long-serving Director of the company purchasing shares opportunistically. Thomas Gayner purchased 5,000 shares of Cable One for Markel last week. Mr. Gayner has served on Cable One’s board since 2015, when the comp...
Investors often get excited when top officials at a company pile into shares of their business. So it was on Friday with Iovance Biotherapeutics (NASDAQ: IOVA) . A flurry of insider buying led to plenty of outsider buying on the market, and pushed the stock's price 17% higher on the...
Cancer-focused biotech Iovance Biotherapeutics, (NASDAQ:IOVA) surged over 15% in the morning hours Friday to record the biggest intraday gain in over a year after several insider purchases at the company. The buyers included Iovance’s (IOVA) general counsel Frederick Vogt who...
The major U.S. equity averages scored another day of notable gains, continuing a rebound that started midway through the week. The Nasdaq led the charge with a 3% advance, as the S&P 500 broke its seven-week-long weekly losing streak. Tech stocks were among the drivers of Friday's rally, ...
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence , following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. It's potentially...
Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (ARCT) +19%. Red Rob...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...